Opexa expects to use proceeds from the financing to continue its Phase IIb clinical study of Tcelna™ in patients with Secondary Progressive MS (SP-MS) and general corporate purposes.
No clinical trial update in over 2 months!
Yes, you're saying right. Now they have some extra money to continue. And other 15 million